Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 2,945 Shares of Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 2,945 shares of the stock in a transaction on Friday, April 4th. The shares were sold at an average price of $33.11, for a total value of $97,508.95. Following the sale, the chief executive officer now owns 479,851 shares in the company, valued at $15,887,866.61. The trade was a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ying Du also recently made the following trade(s):

• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total transaction of $208,449.12.
• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00.
• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Trading Down 6.0 %

ZLAB opened at $27.07 on Wednesday. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -9.77 and a beta of 1.09. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $39.77. The business’s fifty day simple moving average is $32.76 and its 200-day simple moving average is $28.96.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The business had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. On average, equities research analysts predict that Zai Lab Limited will post -2.58 EPS for the current year.

Hedge Funds Weigh In On Zai Lab

A number of large investors have recently bought and sold shares of ZLAB. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the 4th quarter valued at $29,000. Pictet Asset Management Holding SA purchased a new position in Zai Lab in the fourth quarter valued at about $31,000. Barclays PLC raised its holdings in Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after purchasing an additional 2,856 shares in the last quarter. US Bancorp DE lifted its position in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after buying an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. bought a new stake in shares of Zai Lab in the 4th quarter valued at about $210,000. Institutional investors own 41.65% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ZLAB shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price for the company. Bank of America reaffirmed a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, March 13th.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.